List of Genetic Analysis/Screening Companies in France - 11

Depixus SAS, based in Paris, is a life science technology company pioneering a groundbreaking technology based on magnetic force spectroscopy. This innovative technology provides real-time analysis of individual biomolecular interactions at scale, enabling researchers to decode disease mechanisms and unlock faster routes to more effective therapies.

DNA Script was created to revolutionize DNA synthesis with enzymes. Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. The integration of these innovations has resulted in SYNTAX™️, the world’s first benchtop DNA printer powered by enzymatic technology. With continued advancement and innovation, we believe DNA Script’s enzymatic DNA synthesis technology is poised to become the engine of genomics research and personalized medicine.

Epigene Labs is creating the intelligence-augmenting solution for precision oncology research and drug development. Designed by cancer scientists for cancer scientists, the company's mCUBE platform accelerates data-driven drug discovery, biomarker identification, and patient selection -- to bring better treatments to patients faster. Based in Paris and Boston, Epigene Labs was initially incubated at the Harvard Innovation Labs and launched in France with the support of prominent European investors. Epigene Labs has partnerships with world-class cancer research institutes and biopharmaceutical companies.

Ikonisys is a cell based diagnostics company, that markets the proprietary Ikoniscope® Digital Microscope, designed to deliver highly accurate and reliable detection of rare cells. Utilizing advanced molecular and immunological markers, Ikoniscope-built applications are extensively used in the US and Europe for the diagnosis of a variety of cancers.

MSInsight, a French health-tech company, empowers the fight against cancer by revealing actionable information from the genome. We are committed to developing a portfolio of state-of-the-art diagnostic solutions for Microsatellite Instability (MSI) status. MSI has been shown to be an indicator of treatment response, especially for immune checkpoint inhibitors, and as an important pan-cancer biomarker. We aim to propose bioinformatic tools for delivering insights on microsatellite mutational variations using Next-Generation Sequencing (NGS) data. Our flagship product, MSIcare, will be available as a robust diagnostic, prognostic, and theranostic assistant for guiding clinical decision-making.

Odimma is a French biotech company with a unique approach in active personalized cancer immunotherapy. Immunotherapy has revolutionized the treatment of many advanced cancers. Despite this amazing achievement, significant clinical benefits are still limited to 10 to 30% of patients. Odimma believes in the future of precision medicine, and leverages recent advances in the field of immuno-oncology to amplify the efficacy of current therapies, improving lives and making each patient unique. By harnessing the ability of the patient’s own immune system to specifically recognize non-self-targets displayed by the tumor, also called neoantigens, Odimma has designed a next-generation personalized immunization platform that brings a sustainable therapeutic solution to fight the most hard-to-treat cancers. Carried by a team of experts and a supportive environment, we are now preparing our upcoming entry in the clinic

PathoQuest SAS, a spin off of Institut Pasteur, is a biotechnology company offering a game changing metagenomics approach to improving the breadth of pathogen detection.The company’s proprietary next generation sequencing (NGS) based testing approach delivers actionable reports to clinicians, biologists and biopharmaceutical quality assurance managers/production managers.

Scipio bioscience had to cease its operations on 18/09/2024. At Scipio bioscience we were passionate about empowering every researcher to discover the molecular mechanisms of life for better health and a sustainable world. Enabling deeper insights into disease understanding, Scipio wanted to boost the access to and increases the pace of discoveries with its Asteria benchtop kit for easy scRNA-seq sample preparation and its Cytonaut intuitive cloud-based data analysis software for biologists and bioinformaticians alike. Scipio provided all researchers with empowered autonomy to embrace the next step in single-cell, working with unaltered transcriptomic data for the highest-quality results and true biological information. Scipio bioscience was housed in the Paris Santé Cochin incubator, located in the celebrated Parisian Cochin Hospital.

Founded in 2017, SeqOne Genomics headquartered in Montpellier, France, is a fast-growing deep-tech company focused on turning genomic data into medically actionable insights in oncology, rare and inherited diseases. SeqOne clinical genomic analysis platform, powered by explainable AI, provides genomic labs and healthcare professionals with best-in-class accuracy, usability, and automation seamlessly across lab technologies. By streamlining complex multi-omics analysis workflows, we pave the way for a new era of personalized healthcare at scale, where genetic testing becomes as routine as traditional blood work, radically enhancing health outcomes for all. The company has won numerous awards, including the iLab award and the ARC Cancer Foundation’s Hélène Stark prize. It has been nominated twice for the prestigious Prix Galien award. Investors include Elaia, IRDI Capital Investissement, Merieux Equity Partners, Omnes, and Software Club.

Stilla Technologies is a leading global biotechnology company that focuses on accelerating development of next-generation genetic testing by providing researchers and clinicians with a flexible Digital PCR solution for high-resolution genetic analysis and assay development. Stilla’s next-generation Multiplex Crystal Digital PCR™ technology employs cutting-edge microfluidic innovations and integrates the entire dPCR process on a single chip. The naica® system is highly sensitive, fast, and features an easy workflow, higher levels of multiplexing, and intuitive software. Stilla developed the world's first 6-color Digital PCR Platform, providing High Multiplexing and Sensitivity for Advancing Cancer & Liquid Biopsy Studies, Cell & Gene Therapies, Infectious Disease & COVID-19 Research, and Wastewater and Environmental Testing and many more applications. Stilla aims to make Digital PCR a lab commodity in all life sciences areas including research, therapeutics, and the omics. Visit the website and connect on Twitter @StillaTech

Pioneer and expert in blood and tissue microbiota, Vaiomer carries out microbiota studies, in the fields of human and animal health, for preclinical and clinical research, CROs, dermocosmetics, nutraceuticals and pharmaceutical / biotech companies. We perform microbiota studies from a very wide variety of biological samples (blood, adipose tissue, biopsies, tumors, and more classically skin, saliva, faeces, etc.): DNA extraction, quantification by qPCR, sequencing metagenomics, Bioinformatics, Biostatistics. Upstream and downstream of the studies: support for the experimental design and the drafting of study protocols, then for the interpretation and valuation of the results. The role of tissue and blood microbiomes in systemic inflammation is studied in a wide variety of pathologies: https://vaiomer.com/microbiome-applications/ Microbiota can interact with compounds. The study of the action of a compound on the microbiota makes it possible to characterize the modulating, protective or toxic effects of the microbiota on the compound, or of the compound on the microbiota. Taking into account variations in the microbiota also makes it possible to derisk the translation from the animal model to humans: it is a new source of biomarkers of the therapeutic response (responders / non-responders). We are an expert multidisciplinary team (Scientific / Microbiota, Molecular Biology, Bioinformatics and Biostatistics), have a unique technology for samples of low bacterial biomass and a molecular biology laboratory that can process samples from infected subjects (COVID , HIV...)